RxDoctor Payments Data

John Costable, MD

Gastroenterology · Great Neck, NYNPI 1043251184

Payments from drug & device makers

$14,431in general payments, 2019–2025

Across 212 payments — averaging $68.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$11K
  • Ironwood Pharmaceuticals, Inc$843
  • QOL Medical, LLC$763
  • Takeda Pharmaceuticals U.S.A., Inc.$321
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$220
  • Ferring Pharmaceuticals Inc.$217
  • plus $2K from 18 others

What the payments were for

  • Consulting fees$160%
  • Speaking & faculty fees$9,30064%
  • Food & beverage$5,11535%

General payments by program year

19
20
21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$14,431 in reported general payments places this provider in the 80th percentile of 1,682 gastroenterology providers in New York.

See all gastroenterology providers in New York

Medicare billing

Part B allowed, 2024
$192,174
Medicare patients
431
Services billed
938

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
StelaraUstekinumab11$289,624
LinzessLinaclotide88$59,110
CreonLipase/Protease/Amylase25$45,814
Mesalamine28$19,882
Omeprazole-Sodium BicarbonateOmeprazole/Sodium Bicarbonate14$16,853
ClenpiqSod Picosulf/Mag Ox/Citric Ac95$16,103
MounjaroTirzepatide15$14,983
OzempicSemaglutide14$11,536
Omeprazole391$4,266
Pantoprazole Sodium410$3,788
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates62$3,723
Mesalamine ErMesalamine11$3,505
Famotidine199$2,538
Esomeprazole Magnesium37$1,545
Sucralfate33$1,208

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonStelara$156$289,62411 claims
AbbVieLinzess, Creon$10,556$104,924113 claims
Ferring Pharmaceuticals Inc.Clenpiq$217$16,10395 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,682 gastroenterology providers in New York.

Other gastroenterology in Great Neck

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →